Catalyst Pharmaceuticals to Present at Rodman & Renshaw’s 18th Annual Global Investment Conference
September 08 2016 - 8:03AM
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a
biopharmaceutical company focused on developing and commercializing
innovative therapies for people with rare debilitating diseases,
today announced that Patrick J. McEnany, Chief Executive Officer,
and Steven Miller, Ph.D., Chief Operating Officer and Chief
Scientific Officer, will be presenting at Rodman & Renshaw’s
18th Annual Global Investment Conference, which is being held on
September 12-13, 2016 at the New York Palace Hotel in New York.
The presentation will occur on Monday, September
12th at 10:25 AM ET. The presentation materials will be posted at
www.catalystpharma.com in the Investor section under Events and
Presentations.
About Catalyst
Pharmaceuticals
Catalyst Pharmaceuticals is a
biopharmaceutical company focused on developing and commercializing
innovative therapies for people with rare debilitating diseases,
including Lambert-Eaton myasthenic syndrome (LEMS), congenital
myasthenic syndromes (CMS), infantile spasms, and Tourette's
Disorder. Firdapse® for the treatment of LEMS has received
Breakthrough Therapy Designation from the U.S. Food and Drug
Administration (FDA) and orphan drug designation for LEMS, CMS and
myasthenia gravis. Firdapse is the first and only approved drug
in Europe for symptomatic treatment in adults with
LEMS.
Catalyst is also developing CPP-115 to treat
infantile spasms, epilepsy and other neurological conditions
associated with reduced GABAergic signaling, like post-traumatic
stress disorder and Tourette's Disorder. CPP-115 has been
granted U.S. orphan drug designation for the treatment of
infantile spasms by the FDA and has been granted E.U.
orphan medicinal product designation for the treatment of West
Syndrome by the European Commission. In addition,
Catalyst is developing a generic version of Sabril®
(vigabatrin).
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including those factors described in Catalyst's
Annual Report on Form 10-K for the fiscal year 2015 and its other
filings with the U.S. Securities and Exchange
Commission (SEC), could adversely affect Catalyst. Copies of
Catalyst's filings with the SEC are available from
the SEC, may be found on Catalyst's website or may be obtained
upon request from Catalyst. Catalyst does not undertake any
obligation to update the information contained herein, which speaks
only as of this date.
Investor Contact
Brian Korb
The Trout Group LLC
(646) 378-2923
bkorb@troutgroup.com
Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com
Media Contacts
David Schull
Matt Middleman, M.D.
Russo Partners
(212) 845-4271
(212) 845-4272
david.schull@russopartnersllc.com
matt.middleman@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Sep 2023 to Sep 2024